Applying RxPONDER to Clinical Practice

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Catch up on insights into the global development of breast cancer treatments in the global spotlight.

The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.

Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.